Skip to content

Marathon, Genetics, Inflammation and the Cardiovascular System: MAGIC-Trial

Investigation of Myocardial Function and Vascular Adaptation in Association With Genotype in Marathon Runners

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00845286
Acronym
MAGIC
Enrollment
162
Registered
2009-02-18
Start date
2008-09-30
Completion date
2014-08-31
Last updated
2016-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Sudden Cardiac Death

Keywords

exercise, myocardial dysfunction, endothelial dysfunction,, polymorphism

Brief summary

The purpose of the study is to determine the myocardial function and vascular adaptation after strenuous exercise in association with genotype/polymorphisms. We aim to investigate the effects of extreme endurance exercise on the cardiovascular system. Furthermore, the role of the inflammatory response and adaptive mechanisms of the vasculature are examined. Subclinical injuries to the myocardium and vascular wall are being investigated.

Detailed description

Regular exercise leads to an improvement of cardiovascular risc factors in patients with coronary heart disease, atherosclerosis and metabolic disorders. Aerobic exercise has anti-inflammatory effects. In contrast, the exertional exercise of marathon running causes an acute pro-inflammatory impulse. This may lead to myocardial injury and, in case of preexisting plaques, may result in plaque rupture and acute myocardial infarction. We aim to define the critical role of inflammatory markers and cardiovascular risc factors as a predictor of an increased risk for myocardial and endothelial dysfunction in marathon runners. Diagnostic tools include measurements of augmentation index (AIx), arteriolar-venular ratio (AVR) and, for the first time, 2D and 3D echocardiographic measurements such as TDI-imaging and speckle tracking. Inflammatory markers include c-reactive protein (CRP), interleukins and tumor necrosis factor. Additionally, cardiovascular markers are measured. All variations are analysed on the basis of genotype characteristics/polymorphisms.

Interventions

BEHAVIORALMunich Marathon

42,195 km marathon run

Sponsors

Technical University of Munich
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
30 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* men aged 30-60 years

Exclusion criteria

* manifested heart disease * insulin dependent diabetes mellitus * multi drug therapy * GFR\<60ml/min.

Design outcomes

Primary

MeasureTime frame
E/A ratiopre-, post-, one day follow-up

Secondary

MeasureTime frame
LV twistpre-, post-, one day follow-up

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026